Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Searle

Executive Summary

Met with FDA on Aug. 26 to discuss differences between its Calan SR sustained-release verapamil product and Ivax' recently-approved generic version. At the meeting, FDA reaffirmed its position that the Ivax verapamil product is bioequivalent to Searle's Calan SR and will receive an "AB" rating. Searle petitioned the agency on Aug. 5 to stay the granting of an "AB" therapeutic equivalence rating for the Ivax product on the grounds that Ivax had not conducted "necessary" stereochemistry and chiral studies ("The Pink Sheet" Aug. 10, p. 6). The company and FDA have agreed that the issue should be reviewed by FDA's Generic Drugs Advisory Committee; however, the next meeting has not yet been scheduled.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS021412

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel